Er-Kim, an international pharmaceutical company focused on commercializing novel therapies across the EMEA region, has entered into a distribution agreement with Sentynl Therapeutics, Inc. to bring two rare disease treatments, Nulibry and Zokinvy, to patients in select countries throughout Central and Eastern Europe, the Mediterranean, and Eurasian markets.
Nulibry, an injection therapy, is the only treatment approved by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for reducing mortality risk in patients with molybdenum cofactor deficiency (MoCD) Type A. This rare and life-threatening genetic disorder causes severe neurological damage and typically manifests symptoms at birth. If untreated, MoCD can lead to rapid disease progression and premature death in children.
Zokinvy is also the sole approved treatment for Hutchinson-Gilford Progeria Syndrome (HGPS) and certain types of Progeroid Laminopathies in patients aged 12 months and older with a specific body surface area. These conditions cause the body to produce harmful proteins that result in accelerated premature aging and heart complications, with affected young patients aging 8 to 10 times faster than their healthy peers.
Under the terms of the agreement, Er-Kim will distribute Nulibry and Zokinvy across 33 countries, including Poland, Greece, Turkey, Czechia, Romania, Kazakhstan, and Russia.
Cem Zorlular, CEO of Er-Kim, emphasized the importance of timely access to treatments for rare disease patients and expressed pride in expanding availability of these critical therapies. “We are thrilled to collaborate with Sentynl to bring Nulibry and Zokinvy to patients in these regions, offering a vital chance at improved lives,” he said, highlighting Er-Kim’s commitment to broadening drug accessibility through strategic partnerships.
Matt Heck, CEO of Sentynl Therapeutics, described the partnership as a significant milestone that will enable more patients worldwide to benefit from these life-extending therapies. “Our work centers on developing treatments that improve the lives of people with rare diseases, and this collaboration helps us extend that reach,” he added.
This partnership is set to enhance treatment options for patients with these rare and severe conditions across a broad geographic area, marking a major step forward in global rare disease care.